Tyr-3-Octreotide is a synthetic derivative of somatostatin and a somatostatin-receptor analogue. The iodine-123-labelled compound localizes somatostatin-receptor-positive tumours. In this paper two patients are reported in whom somatostatin receptors were demonstrated in vitro. In a 60-year-old female with an islet cell carcinoma of the pancreas, multiple liver metastases and previously unrecognized bone metastases in the right acetabulum could be diagnosed as the reason for a persistent hypoglycaemia. In a 60-year-old male an islet cell carcinoma of the pancreas was localized with123I-Tyr-3-octreotide. The somatostatin receptors were demonstrated in vitro and the tumour was successfully treated with somatostatin. These studies demonstrate that123I-Tyr-3-octreotide offers the possibility of localizing somatostatin-receptor-positive tumours and their metastases. Moreover the method makes it possible to determine the receptor status of a tumour in vivo.

In vitro, In vivo, Iodine-123-Tyr-Octreotide, Pancreatic islet cell carcinoma, Somatostatin receptors
dx.doi.org/10.1007/BF02258458, hdl.handle.net/1765/65244
European Journal of Nuclear Medicine
Department of Nuclear Medicine

Becker, W, Marienhagen, J, Scheubel, R, Saptogino, A, Bakker, W.H, Breeman, W.A.P, & Wolf, F. (1991). Octreotide scintigraphy localizes somatostatin receptor-positive islet cell carcinomas. European Journal of Nuclear Medicine, 18(11), 924–927. doi:10.1007/BF02258458